This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Relling, M. V. Articles by Meyer, U. A. Search for Related Content PubMed PubMed Citation Articles by Relling, M. V. Articles by Meyer, U. A.

Anticancer Drugs as Inhibitors of Two Polymorphic Cytochrome P450 Enzymes, Debrisoquin and Mephenytoin Hydroxylase, in Human Liver Microsomes¹

Department of Pharmacology [M. V. R., W. E. E., R. F.-P., U. A. M.], Biocenter of the University of Basel, Basel, Switzerland, and University of Tennessee [M. V. R., W. E. E.] and St. Jude Children's Research Hospital [W. E. E.], Memphis, Tennessee 38101

To identify potential substrates for the debrisoquin and mephenytoin hydroxylation polymorphisms, we performed in vitro inhibition studies with human liver microsomes and the respective prototype substrates in the absence and presence of several anticancer drugs. (+)-Bufuralol 1'-hydroxylation (as the prototype reaction for the debrisoquin polymorphism) was tested at 5 M substrate concentration and in the presence of cyclophosphamide (0 to 200 M), teniposide (0 to 100 M), vinblastine (0 to 220 M), etoposide (0 to 200 M), flavone acetic acid (0 to 1000 M), or ifosphamide (0 to 200 M). (S)-Mephenytoin 4-hydroxylation was tested at 60 M substrate concentration and in the presence of the same drugs as above; vincristine was also tested at 0 to 200 M. Teniposide competitively inhibited the 4-hydroxylation of (S)-mephenytoin, with a K_i of 12 M (K_m of the reaction = 65 M). Etoposide and flavone acetic acid were weaker inhibitors of this reaction. The only agent to inhibit bufuralol hydroxylation was vinblastine, which did so with a K_i of 90 M (K_m of the enzyme for the substrate = 12 M). We conclude that teniposide and high concentrations of flavone acetic acid could spuriously alter mephenytoin phenotype determination in cancer patients, and that teniposide deserves further investigation as a possible substrate for the genetically regulated mephenytoin hydroxylase.

¹ Supported by Grant NIH R37-36401, by NIH Cancer Center CORE Grant CA 21765, by the American College of Clinical Pharmacy, by a Centers of Excellence grant from the State of Tennessee, by Swiss National Research Foundation Grant 3.817.87, and by ALSAC.

² To whom requests for reprints should be addressed, at St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38101.

Received 8/ 3/88. Accepted 10/ 4/88.

This article has been cited by other articles:

				R. L. Walsky and R. S. Obach VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660. [Abstract] [Full Text] [PDF]

				V. Subrahmanyam, A. B. Renwick, D. G. Walters, P. J. Young, R. J. Price, A. P. Tonelli, and B. G. Lake Identification of Cytochrome P-450 Isoforms Responsible for cis-Tramadol Metabolism in Human Liver Microsomes Drug Metab. Dispos., August 1, 2001; 29(8): 1146 - 1155. [Abstract] [Full Text] [PDF]

				D. E. Burgio, M. P. Gosl, and a. P. J. McNamara Effects of P-glycoprotein Modulators on Etoposide Elimination and Central Nervous System Distribution J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 911 - 917. [Abstract] [Full Text]

				T. Kawashiro, K. Yamashita, X.-J. Zhao, E. Koyama, M. Tani, K. Chiba, and T. Ishizaki A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1294 - 1300. [Abstract] [Full Text]

				N. E. Caporaso and G. L. Shaw Clinical Implications of the Competitive Inhibition of the Debrisoquin-Metabolizing Isozyme by Quinidine Arch Intern Med, October 1, 1991; 151(10): 1985 - 1992. [Abstract] [PDF]